23.00GBp-8.00%Mkt Cap: 31.87M GBpP/E: —Last update: 2026-06-01
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a T…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap31.87M GBp
Enterprise Value31.94M GBp
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.44M GBp
Revenue/Share—
Last Price23.00 GBp
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees5
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.07
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B27.78
EPS (TTM)-0.04
EPS (Forward)-3.60
52W Range
9.50069% of range29.00
52W High29.00 GBp
52W Low9.500 GBp
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-194.91%
ROA-104.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.55M GBp
CapEx (TTM)—
FCF Margin—
FCF Yield-2.94%
Net Debt-2.49M GBp
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.58
Quick Ratio1.58
Book Value/Sh0.0090 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMar 1, 2022
Analyst Consensus
Rating—
Target (Mean)41.60 GBp
Target Range41.60 GBp – 41.60 GBp
# Analysts1
Ownership
Shares Out.138.57M
Float132.30M
Insiders6.49%
Institutions0.00%
Technical
SMA 5019.13 (+20.3%)
SMA 20018.01 (+27.7%)
Beta-0.81
S&P 52W Chg27.94%
Avg Vol (30d)207.38K
Avg Vol (10d)179.39K
Technical Indicators
RSI (14)80.0
MACD0.9135
MACD Signal0.6920
MACD Hist.+0.2215
BB Upper23.63 GBp
BB Middle21.07 GBp
BB Lower18.52 GBp
BB Width24.25%
ATR (14)1.766 GBp
Vol Ratio (20d)4.28x